Assessment of humoral immunity to SARS-CoV-2 among employees of medical organizations in the Republic of Tatarstan

Abstract

BACKGROUND: Since the beginning of the new coronavirus infection pandemic, preventive measures aimed at combating the spread of the pathogen and preventing the development of severe forms of infection and deaths have improved. Despite the absence of a legally established, generally accepted post-vaccination protective value of antibodies to coronavirus, the study of the presence of antibodies and the determination of their amount in the blood serum of the vaccinated population continues.

AIM: This study presents the results of post-vaccination humoral immunity to SARS-CoV-2 in medical organizations regardless of their infectious disease history.

MATERIALS AND METHODS: This study involved employees of medical organizations of the State Autonomous Health Institution “Republican Clinical Dermatovenerologic Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor A.G. Ge” in Kazan and the State Autonomous Health Institution “City Polyclinic No. 3” in Naberezhnye Chelny. Three hundred ninety-three people (including 350 women) were vaccinated with the two-component vaccine GamCovidVac (Sputnik V). After a sufficient amount of time passed for the formation of an immune response, more than 21 days. The blood sera of these 393 people were examined for the determination of specific IgG to SARS-CoV-2 by enzyme immunoassay using the Vector-Best kit (Novosibirsk, Russia). Statistical analysis was performed using StatTech v.3.0.9 (developer, Stattech LLC, Russia).

RESULTS: The median age of the subjects was 47 (Q₁–Q₃: 39–59) years. The mean antibody titer level was 570 (Q₁–Q₃: 128–1150 BAU/ml). A correlation analysis of the relationship between titer levels and age at the time of vaccination was performed. According to the results, a weak direct relationship was established. There was no connection when assessing the antibody titer level dependence on vaccination duration after the second component at the time of checking the titers.

CONCLUSIONS: The ongoing pandemic of a new coronavirus infection with the emergence of new forms of the disease caused by other virus strains, the improvement in prevention methods, requires constant monitoring of the epidemiological situation with the study of the vaccine effectiveness, including the cellular level.

Keywords

SARS-CoV / antibodies / vaccination

References

[1] On the state of sanitary and epidemiological well-being of the population in the Republic of Tatarstan in 2021: state report. Kazan: Federal Service for Supervision of Consumer Rights Protection and Human Welfare; 2022. 359 p. (In Russ).

[2] О состоянии санитарно-эпидемиологического благополучия населения в Республике Татарстан в 2021 г.: государственный доклад. Казань: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2022. 359 с.

[3] Prikaz Ministerstva zdravookhraneniya Rossiyskoy Federatsii ot 06.12.2021 № 1122n “Ob utverzhdenii natsional’nogo kalendarya profilakticheskikh privivok, kalendarya profilakticheskikh privivok po epidemicheskim pokazaniyam i poryadka provedeniya profilakticheskikh privivok” [Order of the Ministry of Health of the Russian Federation dated December 6, 2021 No. 1122n “On approval of the national calendar of preventive vaccinations, the calendar of preventive vaccinations according to epidemic indications and the procedure for conducting preventive vaccinations”] [Internet]. Available from: http://publication.pravo.gov.ru/Document/View/0001202112200070 Accessed: Feb 16, 2023. (In Russ).

[4] Приказ Министерства здравоохранения Российской Федерации от 06.12.2021 № 1122н «Об утверждении национального календаря профилактических прививок, календаря профилактических прививок по эпидемическим показаниям и порядка проведения профилактических прививок» [интернет]. Режим доступа: http://publication.pravo.gov.ru/Document/View/0001202112200070 Дата обращения: 16.02.2023.

[5] Garmash YuYu, Ivanova DA, Borisov SE. Monitoring of antibodies to SARS-CoV-2 in workers of anti-tuberculosis hospital. Tuberculosis and Socially Significant Diseases. 2021;(1):21–31. (In Russ).

[6] Гармаш Ю.Ю., Иванова Д.А., Борисов С.Е. Мониторинг антител к SARS-CoV-2 у работников противотуберкулёзного стационара // Туберкулёз и социально-значимые заболевания. 2021. № 1. С. 21–31.

[7] Samodova OV, Kriger EA, Rogushina NL. Immunity to Vaccine-Preventable Infections in Healthcare Professionals Working in Infectious Diseases Hospitals. Epidemiology and Vaccinal Prevention. 2022;21(4):37–47. (In Russ). doi: 10.31631/2073-3046-2022-21-4-37-47

[8] Самодова О.В., Кригер Е.А., Рогушина Н.Л. Oценка гуморального иммунитета к некоторым вакциноконтролируемым инфекциям у медицинских работников инфекционных стационаров // Эпидемиология и вакцинопрофилактика. 2022. Т. 21, № 4. С. 37–47. doi: 10.31631/2073-3046-2022-21-4-37-47

[9] Semenova EV, Pavlyuk VV, Uvarova MA, Ivanov AV. Features of humoral immunity after COVID-19. Medical Immunology (Russia). 2022;24(2):337–350. (In Russ). doi: 10.15789/1563-0625-FOH-2452

[10] Семенова Е.В., Павлюк В.В., Уварова М.А., Иванов А.В. Особенности гуморального иммунитета после перенесённого COVID-19 // Медицинская иммунология. 2022. Т. 24, № 2. С. 337–350. doi: 10.15789/1563-0625-FOH-2452

[11] Kombarova SYu, Aleshkin AV, Novikova LI. Features of the humoral response to infection, vaccination and revaccination in COVID-19. Bulletin of Experimental Biology and Medicine. 2022;173(6):719–725. (In Russ). doi: 10.47056/0365-9615-2022-173-6-719-725

[12] Комбарова С.Ю., Алешкин А.В., Новикова Л.И. Особенности гуморального ответа на инфекцию, вакцинацию и ревакцинацию при COVID-19 // Бюллетень экспериментальной биологии и медицины. 2022. Т. 173, № 6. С. 719–725. doi: 10.47056/0365-9615-2022-173-6-719-725

[13] Andreev IV, Nechay KO, Andreev AI, et al. Post-vaccination and post-infection humoral immune response to the SARS-CoV-2 infection. Immunologiya. 2022;43(1):18–32. (In Russ). doi: 10.33029/0206-4952-2022-43-1-18-32

[14] Андреев И.В., Нечай К.О., Андреев А.И., и др. Поствакцинальный и постинфекционный гуморальный иммунный ответ на инфекцию SARS-CoV-2 // Иммунология. 2022. Т. 43, № 1. С. 18–32. doi: 10.33029/0206-4952-2022-43-1-18-32

[15] Platonova TA, Golubkova AA, Sklyar MS, et al. On the Issue of Evaluating the Effectiveness of Vaccination of Employees of Medical Organizations against COVID-19. Epidemiology and Vaccinal Prevention. 2022;21(1):61–66. (In Russ). doi: 10.31631/2073-3046-2022-21-1-61-66

[16] Платонова Т.А., Голубкова А.А., Скляр М.С., и др. К вопросу оценки эффективности вакцинации сотрудников медицинских организаций против COVID-19 // Эпидемиология и вакцинопрофилактика. 2022. Т. 21, № 1. С. 61–66. doi: 10.31631/2073-3046-2022-21-1-61-66

[17] Grigoruk SD, Lipskaya OV, Vinokurova TYu, et al. Evaluation of post-vaccination immunity to the new coronavirus infection SARS-COV-2 in oil and gas industry workers. Healthcare of Yugra: experience and innovations. 2022;(1):33–37. (In Russ).

[18] Григорук С.Д., Липская О.В., Винокурова Т.Ю., и др. Оценка поствакцинального иммунитета к новой коронавирусной инфекции SARS-COV-2 у работников нефтегазовой отрасли // Здравоохранение Югры: опыт и инновации. 2022. № 1 (30). С. 33–37.

[19] Platonova TA, Sklyar MS, Golubkova AA, et al. Assessment of specific T-cell immunity in patients who have been ill and vaccinated against COVID-19. Journal Infectology. 2022;14(1):96–104. (In Russ).

[20] Платонова Т.А., Скляр М.С., Голубкова А.А., и др. Оценка специфического Т-клеточного иммунитета у переболевших и вакцинированных против COVID-19 // Журнал инфектологии. 2022. Т. 14, № 1. С. 96–104.

RIGHTS & PERMISSIONS

Eco-vector